Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant

A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (granulocyte-macrophage colony-stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered hepatocellular carcinoma vaccine.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:GM-CSF plasmid DNA hepatocellular carcinoma vaccine adjuvant
Abbreviation:phGM-CSF HCC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search